Abbott Just Swallowed the King of Cancer Screening

Medical devices, for context, was the star quarterback. FreeStyle Libre, Abbott's continuous glucose monitor for diabetes, grew 15% in Q4 2025 alone, hitting $2 billion in quarterly revenue. Electrophysiology products (heart rhythm devices) grew 12.5%. The devices business was cooking. Diagnostics was standing in the corner eating crackers.

So Abbott did what any self-respecting healthcare giant does when an organic growth story stalls: it bought somebody else's growth story.

The Crown Jewel Is a Test You Can Do in Your Pajamas

Exact Sciences built its empire on a deceptively simple idea: what if you could screen for colon cancer without ever leaving your house? The result was Cologuard, a stool-based DNA test that patients complete at home and mail to a lab. No sedation. No scope. No awkward hospital gown.

The product has been used more than 20 million times since launching in 2014, and it's become the preferred non-invasive screening option for average-risk adults 45 and older. Cologuard isn't just a test; it's a franchise.

In 2025, Exact Sciences' screening segment (driven primarily by Cologuard) generated $2.53 billion in revenue. That represented about 78% of the company's total revenue of $3.25 billion. The screening segment alone grew from $2.1 billion in 2024, turbocharged by the launch of Cologuard Plus in early 2025, which reduced false positives by roughly 40% compared to the original version.

To put the revenue concentration in perspective: Cologuard is to Exact Sciences what the iPhone is to Apple. Everything else matters, but this is the thing.

Beyond the Poop Test: A Pipeline Worth Paying For

If Cologuard were the only asset, $23 billion would be a steep price for a single franchise. But Exact Sciences brought a pipeline that reads like a cancer detection buffet.

Oncotype DX, the company's precision oncology test, helps oncologists figure out which breast cancer patients actually need chemotherapy and which can safely skip it. The precision oncology segment pulled in $717 million in 2025 revenue, making it a meaningful business in its own right.

Then there's the next frontier: multi-cancer early detection. Exact Sciences launched Cancerguard, a blood-based screening test designed to catch multiple types of cancer from a single blood draw, in September 2025. The company also has a separate blood-based multi-cancer test backed by the FALCON clinical trial. And in August 2025, Exact Sciences snagged an exclusive U.S. license from Freenome for blood-based colorectal cancer screening, adding yet another tool to the arsenal.

There's also Oncodetect, a molecular residual disease test that launched in Q2 2025 and quickly secured Medicare coverage. It helps detect whether cancer has come back after treatment, catching recurrence earlier than traditional monitoring. Think of it as a smoke alarm for cancer survivors.

All told, Abbott didn't just buy a testing company. It bought a platform positioned across the entire cancer journey: screening, diagnosis, treatment guidance, and monitoring.

The Math: Short-Term Pain, Long-Term Play

Let's talk about what this does to Abbott's financials, because the numbers tell an interesting story.

Abbott expects the deal to add roughly $3 billion in incremental sales for 2026, accelerating its overall sales growth rate by about half a percentage point. That's meaningful for a company projecting 6.5% to 7.5% organic growth this year.

But growth doesn't come free. Abbott anticipates approximately $0.20 in adjusted earnings-per-share dilution for 2026. That's the cost of digesting a $23 billion acquisition: integration expenses, financing costs, and the inevitable friction of merging two very different corporate cultures. Abbott is a 138-year-old diversified healthcare conglomerate; Exact Sciences is a 30-year-old genomics company headquartered in Madison, Wisconsin, where the vibe is decidedly more startup-ish.

The market's reaction to the deal has been surprisingly muted throughout. Abbott's stock dipped 1.7% when the acquisition was announced and popped 2.7% when shareholders approved it. No fireworks. Wall Street seems to have priced this in months ago, treating the closing as a formality rather than a catalyst.

A $60 Billion Market, and Abbott Just Bought the Best Seat

Abbott has repeatedly pointed to a $60 billion addressable market in cancer screening and precision oncology, and it's not hard to see where that number comes from.

The underlying tailwinds are real. Colorectal cancer incidence keeps climbing, especially in younger adults, which is why screening guidelines were expanded to start at age 45. An aging population adds fuel. And there's a massive shift underway from invasive procedures (colonoscopy) toward non-invasive alternatives like stool DNA tests and, increasingly, blood-based liquid biopsies.

Exact Sciences was already the dominant player in non-invasive colorectal screening. Now it has Abbott's global distribution muscle, manufacturing scale, and deep pockets for R&D behind it. For competitors like Freenome, Geneoscopy, and others developing next-generation screening tools, the competitive landscape just got significantly harder.

What Happens Next

The deal is done. Now comes the hard part.

Integration is where big acquisitions go to either thrive or die. Abbott needs to keep Exact Sciences' commercial momentum humming (Q4 2025 screening revenue grew 26% year-over-year) while layering in its own operational discipline. It needs to shepherd that multi-cancer detection pipeline through FDA review without losing the innovative culture that built it. And it needs to convince Wall Street that $0.20 in near-term earnings dilution is worth the long-term payoff.

Exact Sciences had outlined a multi-year productivity plan targeting $150 million in annual savings by 2026. Under Abbott's roof, those efficiency targets will likely get more ambitious, not less.

The bigger question is whether this deal triggers a consolidation wave across cancer diagnostics. Abbott just combined a world-class distribution network with the leading cancer screening franchise. Other diagnostic giants (Roche, Danaher, Siemens Healthineers) may feel compelled to respond. When the biggest kid on the playground gets bigger, everyone else starts looking for allies.

For now, though, the story is simple: Abbott bet $23 billion that the future of cancer detection looks more like a mail-in kit and a blood draw than a colonoscopy suite. Given that 60 million Americans seem to agree, it might be the smartest check they've ever written.

The Startup That Wants to Regrow Your Brain's Missing Neurons

A startup just emerged from stealth with $42 million and early clinical data showing it can grow new brain cells from a patient's own blood, then implant them to restore movement in Parkinson's patients. The results from five patients are turning heads.